Vaxcyte
Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (VAX-31, VAX-24) plus candidates for Group A Strep and Shigella, using its proprietary XpressCF cell-free protein synthesis platform. It targets adults 50+, infants, and global at-risk populations via healthcare providers and public health systems post-approval.
- Company typePublic
- Founded2013
- HeadquartersSan Carlos, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vaxcyte does
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage vaccine innovation company founded in 2013 and headquartered in San Carlos, California, that develops vaccines designed to prevent or treat some of the most common and deadly bacterial infectious diseases worldwide. The company's pipeline targets invasive pneumococcal disease (IPD), Group A Streptococcus, and Shigella—a set of pathogens aligned with the WHO's list of highest-priority antibiotic-resistant threats. Vaxcyte's portfolio is led by VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) currently in Phase 3 adult trials with FDA Breakthrough Therapy designation, followed by VAX-24 (24-valent PCV, Phase 2 infant study), VAX-A1 (Group A Strep, Phase 1), VAX-GI (Shigella, preclinical with NIH funding), and VAX-XL (third-generation PCV, preclinical).
All candidates are built on Vaxcyte's proprietary XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, which enables site-specific, carrier-sparing conjugation that uses approximately half the protein of conventional vaccines while preserving T-cell epitopes. This architecture allows incremental serotypes to be added without compromising immunogenicity—VAX-31 is designed to cover 95%+ of IPD circulating in US adults aged 50+ and 12-40% more serotypes than current standard-of-care PCVs. Vaxcyte has scaled the platform through a GMP facility and is investing up to $1 billion in a new U.S. fill-finish manufacturing facility in North Carolina.
The company has no approved products or product revenue and operates a pre-commercial business model. Upon regulatory approval, Vaxcyte intends to generate revenue through direct sales of its vaccine products to healthcare provider networks, hospitals, public health systems, and government vaccination programs for both adult and pediatric populations. Primary customer segments include adults aged 50+ (PCV), infants and young children (PCV), and global populations at risk from Group A Strep and Shigella. The company held approximately $2.4 billion in cash at last reporting (providing runway through at least end of 2028) and has raised over $4.7 billion cumulatively through repeated public equity offerings since 2022.
Vaxcyte firmographics
Firmographics- Name
- Vaxcyte
- Legal name
- Vaxcyte, Inc.
- Website
- https://vaxcyte.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Vaxcyte is a clinical-stage vaccine company developing broad-spectrum pneumococcal conjugate vaccines (VAX-31, VAX-24) plus candidates for Group A Strep and Shigella, using its proprietary XpressCF cell-free protein synthesis platform. It targets adults 50+, infants, and global at-risk populations via healthcare providers and public health systems post-approval.
- Ownership category
- akta.pro rank
Vaxcyte industry classification
Industry- Product category
- Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industry
- Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)
Keywords
Where Vaxcyte is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Vaxcyte business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Vaccine Product Sales: Vaxcyte is a clinical-stage vaccine company with no current product revenue. The company is developing pneumococcal conjugate vaccines (VAX-31, VAX-24), a Group A Strep vaccine (VAX-A1), and a Shigella vaccine (VAX-GI). Upon regulatory approval, the company will generate revenue through sales of its vaccine products to healthcare providers, governments, and distribution partners.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Vaxcyte product offering
Product offeringCore offering
Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary XpressCF cell-free protein synthesis platform. Its lead candidates are VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines designed to prevent invasive pneumococcal disease in adults and infants, with additional pipeline assets targeting Group A Streptococcus (VAX-A1) and Shigella (VAX-GI). The company is pre-commercial and has no approved products or product revenue, with its first launches planned following regulatory approval.
Product overview
Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary cell-free protein synthesis platform (XpressCF). The company's core PCV franchise includes VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines for the prevention of invasive pneumococcal disease. Beyond pneumococcal vaccines, the pipeline includes VAX-A1 (Group A Streptococcus vaccine in Phase 1), VAX-GI (Shigella vaccine in preclinical), and VAX-XL (third-generation PCV in preclinical). The technology platform enables site-specific, carrier-sparing conjugation for enhanced immunogenicity.
Differentiator
Problem solved
Functional benefit
Products and services
- VAX-31 31-valent pneumococcal conjugate vaccine (PCV) candidate for the prevention of invasive pneumococcal disease (IPD) and pneumonia, advancing through Phase 3 adult clinical program and Phase 2 infant clinical program. It is the broadest-spectrum PCV in clinical development, designed to provide protection against both currently circulating and historically prevalent serotypes.
- VAX-24 24-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 2 infant study for the prevention of invasive pneumococcal disease. Designed to cover more serotypes than any infant PCV on-market today.
- VAX-A1 Novel investigational prophylactic vaccine candidate targeting Group A Streptococcus for the prevention of disease caused by Group A Strep in healthy adults. Currently in Phase 1 first-in-human clinical trial.
- VAX-GI
Quantifiable outcome
- VAX-31 High Dose met non-inferiority criteria for all 20 serotypes common with Prevnar 20 and superiority criteria for all 11 additional serotypes in Phase 1/2 trial of 1,015 healthy adults aged 50+
- +4 more outcomes
Companies that use Vaxcyte
Customer profileSegments4 records
Ideal customer profiles2 records
Vaxcyte technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Vaxcyte partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sutro BiopharmacoreSutro Biopharma has exclusively licensed its XpressCF® cell-free protein synthesis platform to Vaxcyte for vaccine development. This platform enables Vaxcyte to overcome limitations of traditional cell-based methods by separating cellular biochemical components into an extract that includes everything required for transcription, translation and energy production. Sutro has scaled the platform at its GMP facility, and Vaxcyte has also exercised options for XtractCF manufacturing rights totaling $75 million across 2023-2024. Blackstone Life Sciences has a revenue interest on Vaxcyte royalties as part of their partnership with Sutro.
Scale indicators14 records
Recent moves6 records
Expansion highlights5 records
Vaxcyte competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Sells Prevnar 13/20, the dominant pneumococcal conjugate vaccines globally and direct comparator to Vaxcyte's VAX-31/VAX-24. Pfizer's established commercial, manufacturing, and ACIP relationships make it the most consequential incumbent competitor in Vaxcyte's lead indication.
- Merck: Markets Vaxneuvance (PCV15) and V116, a 21-valent PCV, directly competing with Vaxcyte's pneumococcal franchise. Operates one of the largest vaccine commercial organizations globally.
- Moderna: mRNA vaccine platform company with an infectious disease pipeline that overlaps Vaxcyte's strategic ambition of building a broad-spectrum vaccine franchise. Shares the public-market vaccine-innovator narrative and competitor-for-capital dynamic.
- Sanofi: Operates Sanofi Pasteur, a global vaccine business with established conjugate vaccine capabilities and a pediatric/Adult vaccine portfolio. A potential partner or acquirer for Vaxcyte given complementary technology and global commercial reach.
- GSK: Major vaccine manufacturer with a broad infectious disease portfolio. Competes for institutional buyers and public health customers that Vaxcyte targets with its PCV franchise.
Others
- Sutro Biopharma: Licensor of the XpressCF cell-free protein synthesis platform that underpins Vaxcyte's vaccine pipeline. Platform partner and economic stakeholder via royalties and Blackstone revenue interest; also develops ADCs using the same underlying platform.
Emerging players
- Novavax: Clinical-to-commercial-stage vaccine company using a nanoparticle platform for infectious disease targets. Similar late-stage clinical/biotech profile and infectious-disease strategic focus to Vaxcyte.
- BioNTech: mRNA-based vaccine developer with an expanding infectious disease pipeline beyond COVID-19. Competes for talent, capital, and partner attention in the next-generation vaccine space.
- Icosavax: Clinical-stage vaccine developer using a VLP platform for infectious disease targets including RSV and hMPV. Comparable profile as a small-cap, platform-based infectious disease vaccine company.
- Dynavax Technologies: Commercial-stage vaccine company with CpG 1018 adjuvant used in HEPLISAV-B and other infectious disease vaccine programs. Comparable as a smaller, focused vaccine platform company.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Vaxcyte social profiles
Digital presenceVaxcyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vaxcyte leadership team
Management profileNumber of profiles
Profiles11 records
Vaxcyte funding detail
Funding detailFunding overview
Funding rounds13 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vaxcyte M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vaxcyte
What does Vaxcyte do?
Vaxcyte is a clinical-stage vaccine innovation company developing a portfolio of high-fidelity vaccines using its proprietary XpressCF cell-free protein synthesis platform. Its lead candidates are VAX-31 (31-valent) and VAX-24 (24-valent) pneumococcal conjugate vaccines designed to prevent invasive pneumococcal disease in adults and infants, with additional pipeline assets targeting Group A Streptococcus (VAX-A1) and Shigella (VAX-GI). The company is pre-commercial and has no approved products or product revenue, with its first launches planned following regulatory approval.
Is Vaxcyte a public or private company?
Vaxcyte is a public company. It is classified as public and is currently operating.
When was Vaxcyte founded?
Vaxcyte was founded in 2013. It employs 251 to 500 people.
Where is Vaxcyte based?
Vaxcyte is headquartered in San Carlos, United States, in the North America region.
How does Vaxcyte make money?
One revenue line is on record: vaccine Product Sales.
Who are Vaxcyte's main competitors?
Broad incumbents on record are Pfizer, Merck, Moderna, Sanofi and GSK. Sutro Biopharma is listed as an others. Emerging players are Novavax, BioNTech, Icosavax and Dynavax Technologies.
Does Vaxcyte have an API?
No public API is recorded for Vaxcyte.
What industry is Vaxcyte in?
Vaxcyte's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release). Its NAICS code is 325414 and its SIC code is 2836.